These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38913220)

  • 1. Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial.
    Izumi C; Amano M; Fukushima S; Yaku H; Eishi K; Sakaguchi T; Minami M; Yamamoto H; Onda K; Omae K
    Cardiovasc Drugs Ther; 2024 Jun; ():. PubMed ID: 38913220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial.
    Shim CY; Seo J; Kim YJ; Lee SH; De Caterina R; Lee S; Hong GR;
    J Thorac Cardiovasc Surg; 2023 Jan; 165(1):58-67.e4. PubMed ID: 33726903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
    Pasciolla S; Zizza LF; Le T; Wright K
    Clin Drug Investig; 2020 Sep; 40(9):839-845. PubMed ID: 32607688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboembolic and bleeding events after valvular intervention in patients with atrial fibrillation.
    Skogseid EL; Batra G; Westerbergh J; Held C; Christersson C
    Open Heart; 2024 Jan; 11(1):. PubMed ID: 38290732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
    Guimarães HP; de Barros E Silva PGM; Liporace IL; Sampaio RO; Tarasoutchi F; Paixão M; Hoffmann-Filho CR; Patriota R; Leiria TLL; Lamprea D; Precoma DB; Atik FA; Silveira FS; Farias FR; Barreto DO; Almeida AP; Zilli AC; de Souza Neto JD; Cavalcante MA; Figueira FAMS; Junior RA; Moisés VA; Mesas CE; Ardito RV; Kalil PSA; Paiva MSMO; Maldonado JGA; de Lima CEB; D'Oliveira Vieira R; Laranjeira L; Kojima F; Damiani L; Nakagawa RH; Dos Santos JRY; Sampaio BS; Campos VB; Saraiva JFK; Fonseca FH; Pinto IM; Magalhães CC; Ferreira JFM; Lopes RD; Pavanello R; Cavalcanti AB; Berwanger O;
    Am Heart J; 2021 Jan; 231():128-136. PubMed ID: 33045224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing.
    Beller JP; Krebs ED; Hawkins RB; Mehaffey JH; Quader MA; Speir AM; Kiser AC; Joseph M; Yarboro LT; Teman NR; Ailawadi G
    J Thorac Cardiovasc Surg; 2020 Nov; 160(5):1222-1231. PubMed ID: 31706560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients　- A Subanalysis of the ENVISAGE-TAVI AF Trial.
    Watanabe Y; Hayashida K; Yamamoto M; Yamanaka F; Yamasaki K; Naganuma T; Ohno Y; Yamawaki M; Morioka N; Mizutani K; Tada N; Ueno H; Nishina H; Izumo M; Nakajima Y; Ando K; Takagi K; Kimura T; Sugio K; Dangas G; Van Mieghem NM; Hengstenberg C; Chen C; Jin J; Unverdorben M; Saito S
    Circ J; 2022 Oct; 86(11):1756-1763. PubMed ID: 35965066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
    Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
    Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Vitamin K Antagonists Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta-Analysis.
    Cardoso R; Ternes CMP; Justino GB; Fernandes A; Rocha AV; Knijnik L; d'Avila A; Lopes RD
    Am J Med; 2022 Feb; 135(2):228-234.e1. PubMed ID: 34634252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial.
    Hosokawa K; Abe K; Kishimoto J; Kobayakawa Y; Todaka K; Tamura Y; Tatsumi K; Inami T; Ikeda N; Taniguchi Y; Minatsuki S; Murohara T; Yasuda S; Fukuda K; Tsutsui H
    BMJ Open; 2022 Jul; 12(7):e061225. PubMed ID: 37070473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of apixaban versus aspirin for the prevention of latent bioprosthetic aortic valve thrombosis: study protocol for a prospective randomized trial.
    Kopjar T; Gasparovic H; Paar MH; Lovric D; Cerina P; Tokic T; Milicic D
    Trials; 2024 May; 25(1):324. PubMed ID: 38755709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
    Bruins Slot KM; Berge E
    Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Antithrombotic Strategies in Chinese Patients in Sinus Rhythm after Bioprosthetic Mitral Valve Replacement: Early Outcomes from a Multicenter Registry in China.
    Zhang H; Dong Y; Ao X; Fu B; Dong L;
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):1-10. PubMed ID: 32940891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
    ElBardissi AW; DiBardino DJ; Chen FY; Yamashita MH; Cohn LH
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1137-45. PubMed ID: 20303508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and an Aortic Bioprosthetic Valve.
    Miyake M; Takegami M; Obayashi Y; Amano M; Kitai T; Fujita T; Koyama T; Tanaka H; Ando K; Komiya T; Izumo M; Kawai H; Eishi K; Yoshida K; Kimura T; Nawada R; Sakamoto T; Shibata Y; Fukui T; Minatoya K; Tsujita K; Sakata Y; Kimura T; Sugio K; Takita A; Iwakura A; Tamura T; Nishimura K; Furukawa Y; Izumi C;
    Circ J; 2022 Oct; 86(11):1699-1707. PubMed ID: 35811134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study.
    Eikelboom R; Whitlock RP; Sibilio S; Nguyen F; Perez R; Weitz JI; Belley-Cote E
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):109-117. PubMed ID: 36121587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.